Xeris Biopharma Holdings (XERS) Times Interest Earned (2020 - 2026)

Xeris Biopharma Holdings has reported Times Interest Earned for 7 years, with the latest figure at $1.15 in Q1 2026.

• For the quarter ending Q1 2026, Times Interest Earned rose 371.22% year-over-year to $1.15; the trailing twelve-month figure through Mar 2026 stood at $1.25 (up 270.91% YoY), and the FY2025 full-year result was $0.86, up 177.56% from the prior year.
• Times Interest Earned for Q1 2026 stood at $1.15, down from $2.34 in the prior quarter.
• The five-year high for Times Interest Earned was $2.34 in Q4 2025, with the low at -$8.31 in Q1 2022.
• Historically, Times Interest Earned has averaged -$1.69 across 5 years, with a median of -$1.41 in 2023.
• Annual changes were most pronounced in 2024 — Times Interest Earned tumbled 130.78% — and 2025, when it jumped 973.29%.
• Xeris Biopharma Holdings' Times Interest Earned stood at -$3.48 in 2022, then jumped by 59.55% to -$1.41 in 2023, then surged by 115.54% to $0.22 in 2024, then jumped by 973.29% to $2.34 in 2025, then slumped by 51.07% to $1.15 in 2026.
• The last three Times Interest Earned figures came in at $1.15 (Q1 2026), $2.34 (Q4 2025), and $0.92 (Q3 2025), per Business Quant data.